Pharma Focus Asia
MasterControl - Avoid Falling Behind the Pharma Market

A Novel Oral Therapy TTP399 Discovered to Treat Type 1 DiabetesPatients

vTv Therapeutics discovered TTP399 therapy for the treatment of patients with Type 1 diabetes.

TTP399 is a novel, oral, investigational once-daily glucokinase activator. It is considered to be an adjunctive therapy to insulin for the treatment of type 1 diabetes. Moreover, TTP399 shows a significant advantage over other type 1 diabetes therapies.

Low blood sugarlevel being the concern for both doctors and patients providers are apprehensive in utilizing tight glycemic control. Hence, TTP399 therapy offers a potential treatment to an unmet need in the diabetes community.

Type 1 diabetes is a serious, life threateningproblem affecting more than a millionday-to-day. Hypoglycemiais a leading cause of morbidity and potential mortality in the treatment of type 1 diabetes.

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Increasing the likelihood of your drug approvalMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® productsMedical Fair Thailand 20235th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023
MasterControl - 6 Essential Features in an eQMS